Eli Lilly & Co. said it and other drugmakers will ask the Trump administration to pause drug-price negotiations, even as Biden-appointed officials prepare a new list of medicines that should be targeted. "They need to fix it" before negotiating down the price of more drugs, Lilly CEO Dave Ricks said on the sidelines of the JPMorgan Healthcare Conference, referring to the Inflation Reduction Act.